Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074939 | 0.85 | L3MBTL1 (0.31) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL23267828 | 0.81 | ALDH1A1 (0.32) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL25530283 | 0.80 | — | — | |
| SCHEMBL22013342 | 0.76 | GRM4 (0.31) | — | |
| SCHEMBL13316716 | 0.74 | ALDH1A1 (0.47) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL502971 | 0.73 | ALDH1A1 (0.32) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL12463880 | 0.72 | ALDH1A1 (0.33) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL25979247 | 0.72 | KDM4E (0.43) | — | |
| SCHEMBL13172935 | 0.71 | FFAR3 (0.37) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL2625537 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20180016222-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016222-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | ALDH1A1 1763/4885PIK3CD 1627/4885HMGCR 1730/4885 |
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | ALDH1A1 1763/4885PIK3CD 1627/4885HMGCR 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.